Research Highlights on Atopic Dermatitis: Practice-Changing Results From Recent Clinical Trials*

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Review the latest AD management data with Capsule Summaries and gain expert insights from brief commentaries and an on-demand Webcast covering key studies from the 2020 AAAAI, AAD, and RAD conferences.

Highlights on Atopic Dermatitis

Capsule Summary Slidesets

Significantly improved skin inflammation, pain, itch, sleep, and quality-of-life outcomes in patients with moderate to severe AD treated with baricitinib vs placebo.

Released: August 11, 2020

Upadacitinib retreatment was safe and effective in patients who had treatment withdrawn.

Released: July 27, 2020

Clinically significant improvements observed in skin symptoms, itch, and sleep disturbance with baricitinib in adults with moderate to severe AD with comorbid atopic conditions.

Released: July 27, 2020

Dupilumab monotherapy or with concurrent TCS shown to significantly improve signs, symptoms, and quality of life in patients with erythrodermic AD in multiple randomized, placebo-controlled, double-blinded trials.

Released: July 27, 2020

Severe atopic dermatitis was significantly improved for children aged ≥ 6 to < 12 years with dupilumab vs placebo. 

Released: July 20, 2020

Moderate to severe atopic dermatitis was significantly improved for adolescents and adults treated with abrocitinib vs placebo.

Released: July 20, 2020
Provided by Clinical Care Options.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue